Effect of erythromycin on mortality and the host response in critically ill patients with sepsis: a target trial emulation

BACKGROUND: Immunomodulatory therapies that improve the outcome of sepsis are not available. We sought to determine whether treatment of critically ill patients with sepsis with low-dose erythromycin—a macrolide antibiotic with broad immunomodulatory effects—decreased mortality and ameliorated under...

Descripción completa

Detalles Bibliográficos
Autores principales: Reijnders, Tom D. Y., Peters-Sengers, Hessel, van Vught, Lonneke A., Uhel, Fabrice, Bonten, Marc J. M., Cremer, Olaf L., Schultz, Marcus J., Stuiver, Martijn M., van der Poll, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128233/
https://www.ncbi.nlm.nih.gov/pubmed/35610649
http://dx.doi.org/10.1186/s13054-022-04016-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128233/
https://www.ncbi.nlm.nih.gov/pubmed/35610649
http://dx.doi.org/10.1186/s13054-022-04016-x

Ejemplares similares